Classic Familial Adenomatous Polyposis Treatment Market Size & Share, by Treatment Type {Minimal Invasive Colorectal Surgery, Follow-Up Treatment (Colonoscopy, Upper Endoscopy)}; Drug Type (Monotherapy, Combination Therapy Drugs); Distribution Channel (Hospital, Retail, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3109
  • Published Date: Sep 03, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Classic Familial Adenomatous Polyposis Treatment Market size is set to register remarkable growth rate during the forecast period i.e., between 2024-2036.

The growth of the market can be attributed to factors such as the increasing prevalence of colorectal cancer in the world, a personal history of colorectal diseases or polyposis, and growing cases of inherited disorders that heighten the risk of classic FAP. Colorectal cancer is one of the most commonly occurring cancer in the world. In 2018, it was calculated that approximately 1.9 million people globally suffered from the disease. Additionally, excessive intake of tobacco, unhealthy diet and low indulgence in physical activities are considered to be the main causes of FAP. The incidences of sedentary lifestyle are witnessing a notable hike since the last decade, which in turn is expected to drive market growth in the coming years.


Global-Classic-Familial-Adenomatous-Polyposis-Drugs-Market-Overview
Get more information on this report: Request Free Sample PDF

Classic Familial Adenomatous Polyposis Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Occurrence of Colorectal Cancer Worldwide
  • Genetic is History of Polyposis or Colorectal Disorders

Challenges

  • High Treatment Cost of Classic Familial Adenomatous Polyposis 

Classic Familial Adenomatous Polyposis Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Classic Familial Adenomatous Polyposis Treatment Segmentation

The market is segmented by drug type into monotherapy drugs and combination therapy drugs, out of which, the segment for monotherapy drugs is anticipated to hold the largest share in the classic familial adenomatous polyposis treatment market during the forecast period on account of their lesser number of adverse effects, reduced treatment costs, better tolerability and enhanced compliance with treatment. Moreover, on the basis of distribution channel, the hospital pharmacy segment is projected to occupy a significant market share in the near future, which can be credited to the increased interaction of prescribers and health professionals in hospitals, improved access to medical records of patients and better input in making effective prescribing decisions about drugs. 

Our in-depth analysis of the global classic familial adenomatous polyposis treatment market includes the following segments

 

By Treatment Type

  • Minimal Invasive Colorectal Surgery
  • Follow-Up Treatment
    • Colonoscopy
    • Upper Endoscopy
    • Others

 

By Drug Type

  • Monotherapy Drugs
  • Combination Therapy Drugs

By Distribution Channel

 

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Classic Familial Adenomatous Polyposis Treatment Industry - Regional Synopsis

On the basis of geographical analysis, the classic familial adenomatous polyposis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America is poised to dominate majority revenue share by 2036, on the back of high spending in the healthcare sector, growing occurrence of the disease in the United States and ongoing technological advancements to develop effective cure for colorectal disorders. It is evaluated that FAP affects more than 49, 000 families in the United States. FAP occurs in approximately 1 in every 7000 to 10000 individuals in the country. Furthermore, strong presence of major pharmaceutical companies is also evaluated to drive market growth in the region. Similarly, Europe’s market is also assessed to gather a large classic familial adenomatous polyposis treatment market share owing to the growing investments of key players for drug development in the region.

Research Nester
Healthcare Expenditure
Get more information on this report: Request Free Sample PDF

Companies Dominating the Classic Familial Adenomatous Polyposis Treatment Landscape

    • Adhera Therapeutics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cancer Prevention Pharmaceuticals, Inc.
    • Haihe Biopharma Co., Ltd.
    • StemSynergy Therapeutics, Inc.
    • SLA Pharma AG
    • DNAlite Therapeutics Inc
    • GLW International
    • TherapyX Inc
    • Thetis Pharmaceuticals LLC
    • Zikani Therapeutics Inc

In the News

·  September, 2020: Cancer Prevention Pharmaceuticals submitted a new Drug Application to the U.S. Food and Drug Administration (FDA) for CPP-1X/sul for treating familial adenomatous polyposis (FAP) among adults.

Author Credits:  Radhika Pawar


  • Report ID: 3109
  • Published Date: Sep 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Classic Familial Adenomatous Polyposis Treatment Market size is set to register remarkable growth rate during the forecast period i.e., between 2024-2036.

Rising occurrence of colorectal cancer worldwide and genetic history of polyposis or colorectal disorders will propel the market growth.

North America is poised to dominate majority revenue share by 2036, on the back of high spending in the healthcare sector, growing occurrence of the disease in the United States and ongoing technological advancements to develop effective cure for colorectal disorders.

The major players in the market are Adhera Therapeutics, Inc., Cancer Prevention Pharmaceuticals, Inc., Haihe Biopharma Co., Ltd., StemSynergy Therapeutics, Inc., and others.
Classic Familial Adenomatous Polyposis Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample